MPO-ANCA GN can be characterized as both a type II antibody-mediated disease (due to the effects of ANCA) and a type IV cell-mediated hypersensitivity (due to the Th1 cell-mediated aspect of the disease) as per Gell and Coombs classification (45). Here, MPO is linked to ganglioneuroma.